Assessment of the Hemophagocytic Lymphohistiocytosis HScore in Patients With Coronavirus Disease 2019

Kristina E N Clark; William D Nevin; Tabitha Mahungu; Helen Lachmann; Animesh Singh

doi:10.1093/cid/ciaa1463

Assessment of the Hemophagocytic Lymphohistiocytosis HScore in Patients With Coronavirus Disease 2019

Clin Infect Dis. 2021 Nov 2;73(9):e3110-e3112. doi: 10.1093/cid/ciaa1463.

Authors

Kristina E N Clark¹, William D Nevin², Tabitha Mahungu², Helen Lachmann³, Animesh Singh⁴

Affiliations

¹ Department for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom.
² Department of Infectious Diseases, Royal Free Hospital London NHS Foundation Trust, London, United Kingdom.
³ UK National Amyloidosis Centre, University College London, London, United Kingdom.
⁴ Department of Rheumatology, Royal Free Hospital London NHS Foundation Trust, London, United Kingdom.

Abstract

The clinical manifestation of moderate to severe coronavirus disease 2019 (COVID-19) has parallels to secondary hemophagocytic lymphohistiocytosis (HLH) both clinically and based on molecular inflammatory response. We found no evidence to support the utility of risk-stratifying COVID-19 patients using risk scoring methodology designed for HLH.

Keywords: HLH; COVID-19; HScore; cytokine storm.

MeSH terms

COVID-19*
Humans
Lymphohistiocytosis, Hemophagocytic* / diagnosis
Risk Factors
SARS-CoV-2